Related Experiment Video
Updated: Jul 11, 2025
Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
Published on: March 29, 2024
High Dose of Metformin Decreases Susceptibility to Occlusive Arterial Thrombosis in Diabetic Mice
Roberto I Mota Alvidrez1,2,3,4,5,6,7, Gowtham K Annarapu3, Amudan J Srinivasan1
1Trauma and Transfusion Medicine Research Center, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA 15213.
Introduction:
Metformin is the most prescribed medication in Diabetes Mellitus(DM). Metformin has shown to decrease mean platelet volume, with promising antiplatelet effects. High doses of Metformin have also been associated with hypercoagulation. We hypothesize that Metformin will protect DM mice from occlusive arterial thrombus formation by altering platelet activation and mitochondrial bioenergetics.
Methods:
DM was developed by low dose of Streptozotocin, non-DM (healthy) mice are controls. Either vehicle or Metformin was administered twice daily via oral gavage for 7-days. Ferric chloride (FeCl3) arterial thrombosis and tail bleeding time were performed. Whole blood aggregometry, platelet activation/adhesion and mitochondrial bioenergetics were evaluated.
Results:
Metformin decreased susceptibility of DM mice to arterial thrombosis. Platelet bioenergetics show DM mice have increased platelet mitochondrial respiration, but no differences were observed with Metformin treatment. In non-DM (healthy) mice, Metformin modulated ADP-dependent increase in platelet adhesion. Non-DM (healthy) mice, Metformin shortens bleeding time with faster thrombotic occlusion. Metformin also increased platelet mitochondrial maximal respiration and spare respiratory capacity uniquely in non-DM (healthy) mice.
Conclusion:
Metformin regulates platelet bioenergetics and ADP-mediated platelet function in DM mice which attenuates susceptibility to arterial thrombosis. Future studies will evaluate clinically relevant doses of Metformin that regulates thrombotic function in diabetic platelets.
Insights
Metformin reduces arterial thrombosis in diabetic mice by altering platelet function. This common diabetes medication shows potential for managing blood clot risks in patients with diabetes mellitus.
Area of Science:
- Biomedical Science
- Pharmacology
- Cardiovascular Research
Background:
- Metformin is a widely prescribed drug for Diabetes Mellitus (DM).
- Metformin exhibits potential antiplatelet effects by decreasing mean platelet volume.
- High doses of Metformin have been linked to hypercoagulation, necessitating further investigation.
Purpose of the Study:
- To investigate Metformin's protective effects against occlusive arterial thrombus formation in diabetic mice.
- To determine Metformin's impact on platelet activation and mitochondrial bioenergetics in the context of diabetes.
Main Methods:
- Diabetes Mellitus (DM) was induced in mice using Streptozotocin; healthy mice served as controls.
- Mice received either vehicle or Metformin via oral gavage for seven days.
- Arterial thrombosis, tail bleeding time, platelet aggregometry, activation, adhesion, and mitochondrial bioenergetics were assessed.
Main Results:
- Metformin treatment decreased arterial thrombosis susceptibility in diabetic mice.
- Diabetic mice exhibited increased platelet mitochondrial respiration, unaffected by Metformin.
- In healthy mice, Metformin modulated ADP-dependent platelet adhesion and shortened bleeding time, indicating faster thrombotic occlusion.
Conclusions:
- Metformin regulates platelet bioenergetics and ADP-mediated function in diabetic mice, attenuating arterial thrombosis risk.
- Further research is needed to explore clinically relevant doses of Metformin for regulating thrombotic function in diabetic platelets.
